PF-610355

{{short description|Respiratory medication}}

{{Drugbox

| Watchedfields = changed

| verifiedrevid =

| IUPAC_name = N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2-{[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide

| image = PF-610355.svg

| width = 230

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| routes_of_administration = Inhalation

| legal_status = Development terminated

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 862541-45-5

| ATC_prefix = None

| ATC_suffix =

| PubChem = 11505444

| IUPHAR_ligand =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 9680243

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = ZH5SMU97AJ

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 1240967

| C = 34 | H = 39 | N = 3 | O = 6 | S = 1

| smiles =

| StdInChI =

| StdInChIKey =

}}

PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable{{cite journal | vauthors = Diderichsen PM, Cox E, Martin SW, Cleton A, Ribbing J | title = Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease | journal = British Journal of Clinical Pharmacology | volume = 76 | issue = 5 | pages = 752–62 | date = November 2013 | pmid = 23323609 | pmc = 3853534 | doi = 10.1111/bcp.12080 }} ultra-long-acting β₂ adrenoreceptor agonist{{cite journal | vauthors = Cazzola M, Calzetta L, Matera MG | title = β(2) -adrenoceptor agonists: current and future direction | journal = British Journal of Pharmacology | volume = 163 | issue = 1 | pages = 4–17 | date = May 2011 | pmid = 21232045 | pmc = 3085864 | doi = 10.1111/j.1476-5381.2011.01216.x }} (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer.{{cite web|title=Pfizer Pipeline as of January 27, 2010|url=http://www.pfizer.com/sites/default/files/product-pipeline/FINAL_27Jan10_Disclosed%20Portfolio.pdf|publisher=Pfizer Inc.|access-date=9 April 2016|page=6|archive-date=6 September 2015|archive-url=https://web.archive.org/web/20150906120238/http://www.pfizer.com/sites/default/files/product-pipeline/FINAL_27Jan10_Disclosed%20Portfolio.pdf|url-status=dead}} It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically mediated adverse events.{{cite journal | vauthors = Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, Brown AD, Yeadon M, Perros-Huguet C, Trevethick MA, Clarke NP, Webster R, Jones RM, Burrows JL, Feeder N, Taylor SC, Spence FJ | display-authors = 6 | title = Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup | journal = Journal of Medicinal Chemistry | volume = 53 | issue = 18 | pages = 6640–52 | date = September 2010 | pmid = 20804199 | doi = 10.1021/jm1005989 }} Its in vivo duration on action confirmed its potential for once-daily use in humans. {{cite book |editor1-last=Acton |editor1-first=Q. Ashton | name-list-style = vanc |title=Issues in Medical Chemistry Edition |publisher=ScholarlyEditions |isbn=978-1-464-96440-4 |date=2012-01-09 }}

The investigation and development of PF-610355 were discontinued in 2011,{{cite web|title=AdisInsight: PF 610355|url=http://adisinsight.springer.com/drugs/800025582|publisher=Springer International Publishing AG|access-date=25 March 2016}} likely for strategic and regulatory reasons.{{cite journal | vauthors = Cazzola M, Page CP, Rogliani P, Matera MG | title = β2-agonist therapy in lung disease | journal = American Journal of Respiratory and Critical Care Medicine | volume = 187 | issue = 7 | pages = 690–6 | date = April 2013 | pmid = 23348973 | doi = 10.1164/rccm.201209-1739PP | hdl = 2108/89635 | hdl-access = free }}